U.S. Markets closed

Opiant Pharmaceuticals, Inc. (OPNT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
6.565-0.13 (-2.01%)
At close: 3:52PM EDT
People also watch
Interactive chart
Previous Close6.700
Bid0.000 x
Ask0.000 x
Day's Range6.550 - 6.565
52 Week Range5.010 - 9.060
Avg. Volume2,298
Market Cap13.37M
PE Ratio (TTM)1.46
EPS (TTM)4.51
Earnings DateJun 7, 2017 - Jun 12, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.67
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Opiant Pharmaceuticals, Inc. Announces Results of Positron Emission Tomography (PET) Study of Naloxone Nasal Spray

    SANTA MONICA, Calif., March 27, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced the completion ...

  • Zacks Small Cap Research2 months ago

    OPNT: Looking to Have a Transformative 2017

    During the quarter, the company signed an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones are met. Once SWK receives back 1.5 times their investment, Opiant will receive at least 90% of future NARCAN® royalties and milestone payments. Total revenue for the fiscal second quarter was $13.535 million, compared to $6.86 million during the three months ending Jan. 31, 2016.

  • Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q2, 2017 By the Numbers : March 22, 2017
    Capital Cube2 months ago

    Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q2, 2017 By the Numbers : March 22, 2017

    Categories: Yahoo Finance Get free summary analysis Opiant Pharmaceuticals, Inc. reports financial results for the quarter ended January 31, 2017. We analyze the earnings along side the following peers of Opiant Pharmaceuticals, Inc. – GW Pharmaceuticals PLC Sponsored ADR and Arena Pharmaceuticals, Inc. (GWPH-US and ARNA-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)